Literature DB >> 17209557

Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein.

Cristian Follmer1, Luciana Romão, Carla M Einsiedler, Thaís C R Porto, Flávio Alves Lara, Marlos Moncores, Gilberto Weissmüller, Hilal A Lashuel, Peter Lansbury, Vivaldo Moura Neto, Jerson L Silva, Debora Foguel.   

Abstract

Parkinson's disease (PD) is characterized by the presence of cytoplasmic inclusions composed of alpha-synuclein (alpha-syn) in dopaminergic neurons. This suggests a pivotal role of dopamine (DA) on PD development. Here, we show that DA modulates differently the stability of protofibrils (PF) and fibrils (F) composed of wild type or variants of alpha-syn (A30P and A53T) as probed by high hydrostatic pressure (HHP). While in the absence of DA, all alpha-syn PF exhibited identical stability, in its presence, the variant-composed PF acquired a greater stability (DAPFwt < DAPFA30P = DAPFA53T), implying that they would last longer, which could shed light onto why these mutations are so aggressive. When alpha-syn was incubated for long times (18 days) in the presence of DA, we observed the formation of F by electronic microscopy, suggesting that the PF trapped in the presence of DA in short times can evolve into F. The stability of F was also altered by DA. DAFwt was more labile than Fwt, indicating that the former would be more susceptible to breakage. PFA30P and DAPFA30P, when added to mesencephalic and cortical neurons in culture, decreased the number and length of neurites and increased the number of apoptotic cells. Surprisingly, these toxic effects of PFA30P and DAPFA30P were practically abolished with HHP treatment, which was able to break the PF into smaller aggregates, as seen by atomic force microscopy. These results suggest that strategies aimed at breaking and/or clearing these aggregates is promising in alleviating the symptoms of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17209557     DOI: 10.1021/bi061871+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

Review 1.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

2.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

Review 3.  The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Authors:  Danielle E Mor; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Mov Disord       Date:  2019-01-11       Impact factor: 10.338

4.  The structure of dopamine induced alpha-synuclein oligomers.

Authors:  Agata Rekas; Robert B Knott; Anna Sokolova; Kevin J Barnham; Keyla A Perez; Colin L Masters; Simon C Drew; Roberto Cappai; Cyril C Curtain; Chi L L Pham
Journal:  Eur Biophys J       Date:  2010-03-23       Impact factor: 1.733

5.  The dopamine receptor agonist apomorphine stabilizes neurotoxic α-synuclein oligomers.

Authors:  Vanderlei de Araujo Lima; Rodrigo Esquinelato; Phelippe Carmo-Gonçalves; Lucas Alex do Nascimento; Hudson Lee; David Eliezer; Luciana Romão; Cristian Follmer
Journal:  FEBS Lett       Date:  2021-12-29       Impact factor: 4.124

6.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

7.  Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.

Authors:  Vanderlei de Araújo Lima; Lucas Alex do Nascimento; David Eliezer; Cristian Follmer
Journal:  ACS Chem Neurosci       Date:  2018-11-05       Impact factor: 4.418

Review 8.  Modulation of alpha-synuclein aggregation by dopamine: a review.

Authors:  Su Ling Leong; Roberto Cappai; Kevin Jeffrey Barnham; Chi Le Lan Pham
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996

Review 9.  In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Authors:  Marie-Francoise Chesselet
Journal:  Exp Neurol       Date:  2007-08-23       Impact factor: 5.330

10.  Molecular and neurochemical mechanisms in PD pathogenesis.

Authors:  Irmgard Paris; Jorge Lozano; Carolina Perez-Pastene; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2009-05-20       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.